JMX1122

JMX1122 is a preclinical-stage proteolysis-targeting chimera (PROTAC) protein degrader designed to target and degrade signal transducer and activator of transcription 3 (STAT3). Developed by researchers at the Louisiana State University Health Sciences Center (LSUHSC) and the University of Texas Medical Branch (UTMB), JMX1122 is based on the small-molecule STAT3 inhibitor HJC0152. In preclinical studies, JMX1122 has demonstrated potent antiproliferative and colony-formation inhibitory activities against triple-negative breast cancer (TNBC) and estrogen receptor (ER)-positive breast cancer cell lines. Unlike its parent compound HJC0152, which primarily inhibits STAT3 phosphorylation, JMX1122 induces robust degradation of the total STAT3 protein, leading to apoptosis in breast cancer cells.